SYS-CON MEDIA Authors: Peter Silva, Kevin Jackson, Jessica Qiu, Dana Gardner, Dan Stolts

News Feed Item

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013

-- FY13 Total Sales Up 10.0% to $203.4 Million --

BEIJING, March 12, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2013.

Fourth Quarter 2013 Financial Highlights

  • Total sales in the fourth quarter of 2013 increased by 25.3% to $42.6 million from $34.0 million in the same quarter of 2012.
  • Gross profit increased by 12.9% to $27.0 million from $23.9 million in the same quarter of 2012. Gross margin fell to 63.4% in the fourth quarter of 2013, from 70.4% in the fourth quarter of 2012 primarily due to certain non-recurring, higher-than-usual plasma costs for a portion of the products sold in the quarter.
  • Income from operations decreased by 10.4% to $12.5 million from $13.9 million in the same quarter of 2012. Operating margin decreased to 29.3% in the fourth quarter of 2013 from 41.0% in the same quarter of 2012 mainly due to higher selling expenses resulting from increased Placenta Polypeptide product shipments.
  • Net income attributable to the Company increased by 52.0% to $8.8 million from $5.8 million in the same quarter of 2012. Fully diluted net income per share was $0.32 in the fourth quarter of 2013 as compared to $0.21 in the same quarter of 2012.
  • Non-GAAP adjusted net income attributable to the Company was $9.6 million, representing a 32.2% increase from $7.3 million in the same quarter of 2012. Non-GAAP adjusted net income per share was $0.35, compared to $0.27 in the same quarter of 2012.

Fiscal Year 2013 Financial Highlights

  • Total sales in 2013 increased by 10.0% to $203.4 million from $184.8 million in 2012.
  • Gross profit in 2013 increased by 9.4% to $137.9 million from $126.0 million in 2012. Gross margin remained relatively stable at 67.8% and 68.2% in 2013 and 2012, respectively.
  • Income from operations in 2013 increased by 16.7% to $86.9 million from $74.5 million in 2012. Operating margin increased to 42.7% in 2013 from 40.3% in 2012.
  • Net income attributable to the Company increased by 20.7% to $54.6 million from $45.2 million in 2012. Fully diluted net income per share was $1.96 in 2013 as compared to $1.62 in 2012.
  • Non-GAAP adjusted net income attributable to the Company was $59.0 million, representing a 22.9% increase from $48.0 million in 2012. Non-GAAP adjusted net income per share was $2.12, compared to $1.79 in 2012.

Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We are proud of the material increase to our year-over-year sales and net income results in spite of a temporary production suspension for GMP renewal at our Guizhou facility midway through the year and from a challenging comparison to strong 2012 financial results. Our steady growth was supported by rising market demand, favorable product pricing, stringent cost control measures, and most importantly, the expansion of our product portfolio and transition to a more profitable product mix. In 2013, we experienced a 16% increase in our plasma collection volume, mostly through organic growth at existing centers. In addition we added one new plasma collection center in Cao County and enlarged collection territory at two collection centers of our Guizhou subsidiary. During the year, we also improved our plasma utilization efficiency following the launch of our Factor VIII products. We are particularly pleased to have amassed a market share of 19% in China's Factor VIII market during the first year of its launch."

"In 2013, we accomplished a primary corporate goal of full compliance with Good Manufacturing Practice ("GMP") standards at our various facilities. Through our efforts, our Shandong Taibang facility obtained the renewal of its GMP certification for plasma production in June 2013, while our Guizhou Taibang facility completed its GMP upgrade in January 2014. Moreover, in January 2014, we received GMP certification for the Placenta Polypeptide production facility at Guizhou. We are expecting to receive GMP certification and resume production in the second quarter as planned for our plasma production facility. As such, we expect higher growth with more products available for sales starting in the third quarter this year. We are confident that, with these upgrades, we can enhance our operating efficiency to meet growing market demand moving forward."

Mr. Gao continued, "In an effort to expand our product portfolio and increase profitability, we continue to make progress in several important areas during 2013 that can contribute to our 2014 financial performance.  We obtained SFDA approval to manufacture Human Prothrombin Complex Concentrate ("PCC") at our Guizhou Taibang facility and also received SFDA manufacturing approval for a new dosage of FVIII (300IU), further reinforcing our industry leadership.  We also initiated phase III clinical trials for Human Fibrinogen."

"We continue our efforts to enhance our shareholding structure and increase shareholder value. During the last three quarters, we closed two share repurchase transactions, where we repurchased an aggregate 3.98 million shares of common stock for a total consideration of $99.6 million. The repurchased shares represent approximately 14.76% of the total common stock outstanding in early August prior to the first share repurchase."

Mr. Gao concluded, "Looking into 2014, we are confident that we can further capitalize on growing demand for our products and achieve greater levels of revenue growth. We anticipate our plasma collection volume will continue to rise in both Shandong and Guizhou. We also see great opportunity to further penetrate sales of IVIG and higher-margin hyper-immune products in certain markets and increase our production and sales of Placenta Polypeptide products. We expect to strengthen our market leadership in human coagulation products, including FVIII, and introduce PCC to the market in 2014.  With the strength of our current product portfolio and planned growth initiatives, we believe 2014 will be another promising year for our company."

Fourth Quarter 2013 Financial Performance

Total sales in the fourth quarter of 2013 were $42.6 million, representing an increase of 25.3% from $34.0 million in the same quarter of 2012. The increase was mainly due to the substantial increase in albumin sales in Shandong and increased sales from Placenta Polypeptide in Guizhou.

Cost of sales increased by 54.7% to $15.6 million from $10.1 million in the same quarter of 2012. Cost of sales as a percent of total sales was 36.6%, compared to 29.6% in 2012. Volume and percentage increases in cost of sales were mainly caused by a portion of products sold during the quarter with higher-than-usual plasma cost resulting from certain non-recurring charges.

Total operating expenses in the fourth quarter of 2013 increased by 45.4% to $14.5 million from $10.0 million in 2012. As a percentage of total sales, total operating expenses increased to 34.1% from 29.4% in 2012. Volume and percentage increases in total operating expenses were mainly due to higher selling expenses resulting from increased Placenta Polypeptide product shipments.

Income from operations decreased by 10.4% to $12.5 million from $13.9 million in the same quarter of 2012 for the reasons states above. Operating margin decreased to 29.3 % in the fourth quarter of 2013 from 41.0% in the same quarter of 2012.

Net income attributable to the Company increased by 52.0% to $8.8 million from $5.8 million in the same quarter of 2012. Fully diluted net income per share was $0.32 in the fourth quarter of 2013 compared to $0.21 in the same quarter of 2012.

Non-GAAP adjusted net income attributable to the Company was $9.6 million, or $0.35 per diluted share, in the fourth quarter of 2013, representing a 32.2% increase from $7.3 million, or $0.27 per diluted share, in the fourth quarter of 2012.

Fiscal Year 2013 Financial Performances

Total sales in 2013 were $203.4 million, an increase of 10.0% from $184.8 million in 2012. Excluding foreign exchange influence, the increase in sales was primarily attributable to a mix of price and volume increases in certain plasma based products.

During 2013, human albumin products and IVIG products remained the largest two sales contributors. The average price for human albumin products increased by approximately 10.1%, mainly due to the increase of retail price ceiling announced by NDRC at the beginning of 2013, which allowed the Company to increase ex-factory prices in certain regional markets. The average price for IVIG products remained relatively stable in 2013 as compared to 2012.

As a percentage of total sales, revenue from human albumin products was 44.1% in 2013 as compared to 44.6% in 2012. Sales volume for human albumin products decreased slightly by 1.2% in 2013, primarily due to the production suspension for GMP renewal in Guizhou Taibang starting from June 2013.

As a percentage of total sales, revenue from IVIG products was 38.0% in 2013 as compared to 39.0% in 2012. Sales volume for IVIG products increased by 6.0% in 2013, as a result of the Company's efforts to engage new distributors to promote IVIG sales in certain tier-one cities.

For the year ended December 31, 2013, the sales increase of other products was mainly attributable to the newly-launched human coagulation factor VIII (200IU) in Shandong Taibang, which accounted for 2.1% of total sales in 2013.

Cost of sales increased by 11.3% to $65.5 million in 2013 from $58.8 million in 2012. Cost of sales as a percentage of total sales was 32.2%, as compared to 31.8% in 2012. Volume and percentage increases in cost of sales were mainly due to increased sales activities and increased raw plasma collection costs resulting from higher compensation paid to plasma donors.

Gross profit increased by 9.4% to $137.9 million in 2013 from $126.0 million in 2012. Gross margin remained relatively stable at 67.8% and 68.2% in 2013 and 2012, respectively. 

Total operating expenses in 2013 decreased slightly by 1.1% to $50.9 million from $51.5 million in 2012. As a percentage of total sales, total operating expenses decreased to 25.0% from 27.9% in 2012.

Selling expenses in 2013 decreased by 26.2% to $10.6 million from $14.4 million in 2012. As a percentage of total sales, selling expenses were 5.2%, down from 7.8% in 2012. The decrease was primarily due to the increased direct sales to the hospitals since the second half of 2012.

General and administrative expenses in 2013 increased by 6.0% to $36.1 million from $34.0 million in 2012. The increase in general and administrative expenses was mainly due to an increase in expenses related to payroll and employee benefits as a result of general salary increases, and an increase in non-recurring legal expenses. As a percentage of total sales, general and administrative expenses were 17.7% and 18.4% in 2013 and 2012, respectively.

Research and development expenses in 2013 were $4.2 million, representing an increase of 39.3% from $3.0 million in 2012. As a percentage of total sales, research and development expenses for the years ended December 31, 2013 and 2012 were 2.1% and 1.6%, respectively. The increase in research and development expenses was primarily due to the engagement of external expertise to improve production yields on certain hyper-immune products during the year ended December 31, 2013. In addition, China Biologic started the clinical trial program on human fibrinogen in 2013.

Income from operations in 2013 was $86.9 million, representing an increase of 16.7% from $74.5 million in 2012. Operating margin increased to 42.7% in 2013 from 40.3% in 2012.

Income tax expense in 2013 was $15.5 million, as compared to $15.2 million in 2012. The effective income tax rates were 16.8% and 18.7% for the years ended December 31, 2013 and 2012, respectively.

Net income attributable to the Company increased by 20.7% to $54.6 million in 2013, from $45.2 million in 2012. Net margins were 26.9% and 24.5% for the years ended December 31, 2013 and 2012, respectively. Fully diluted net income per share was $1.96, as compared to $1.62 in 2012.

Non-GAAP adjusted net income attributable to the Company was $59.0 million or $2.12 per diluted share in 2013, compared to $48.0 million or $1.79 per diluted share in 2012.

Non-GAAP adjusted net income and diluted earnings per share in 2013 excluded $4.4 million of non-cash employee share-based compensation expenses.

As of December 31, 2013, the Company had cash and cash equivalents of $144.1 million, compared to $129.6 million as of December 31, 2012.

Net cash provided by operating activities for the year ended December 31, 2013 was $74.3 million, as compared to $71.1 million for the same period of 2012. The increase in inventory for the years ended December 31, 2013 and 2012 were $10.4 million and $3.8 million, respectively. The increase in inventories was mainly due to increase of raw materials due to the continued supply of plasma by plasma stations of Guizhou Taibang during the production suspension for GMP renewal. The increase in accounts receivable was $5.7 million, largely in line with sales expansion in 2013. Accounts receivable turnover days decreased slightly from 28 days in 2012 to 26 days in 2013. 

Net cash used in investing activities for the twelve months ended December 31, 2013 was $25.6 million compared to $26.8 million in the prior year period.

Net cash used in financing activities for the year ended December 31, 2013 was $38.5 million compared to $5.1 million in the prior year period. Net cash used in financing activities in 2013 mainly consisted of a payment of $29.6 million for share repurchase and a dividend of $16.9 million paid by the Company's subsidiaries to the non-controlling interest shareholders, partially offset by proceeds of $5.4 million from the exercise of the stock options and contribution of $2.9 million from a non-controlling interest shareholder.

Outlook

For the full year of 2014, the Company expects total sales to be in the range of $230million to $240 million. This guidance assumes only organic growth and excludes acquisitions and necessarily assumes no significant adverse price changes during 2014. The Company estimates full year non-GAAP adjusted net income to be in the range of $67 million to $69 million

This forecast reflects the Company's current and preliminary views, which are subject to change.

Conference Call

The Company will host a conference call at 8:00 am, Eastern Time on Thursday, March 13, 2014, which is 8:00 pm, Beijing Time on March 13, 2014, to discuss fourth quarter and fiscal year 2013 results and answer questions from investors. Listeners may access the call by dialing:

US:

+1-866-652-5200

International:

+1-412-317-6060

Hong Kong:

800-905-945

China:

400-120-1203

Passcode:

10042209

A telephone replay will be available one hour after the conclusion of the conference all through 9:00 am, Eastern Time on March 20, 2014. The dial-in details are: 

US:

+1-877-344-7529

International:

+1-412-317-0088

Passcode:

10042209

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Non-GAAP Disclosure

This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of warrants. To supplement the Company's unaudited condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2013, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:     

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
E-mail: [email protected]

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: [email protected]

Financial statements follow.

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME




For the Years Ended 



December 31, 


December 31, 


December 31, 



2013


2012


2011



USD


USD


USD

Sales


203,356,856


184,813,495


153,092,289

Cost of sales


65,484,153


58,835,998


46,017,661

Gross profit 


137,872,703


125,977,497


107,074,628








Operating expenses 







       Selling expenses


10,643,149


14,421,258


14,595,794

       General and administrative expenses 


36,073,871


34,034,360


31,519,824

       Research and development expenses 


4,223,165


3,032,719


3,978,233

       Impairment loss of goodwill 


-


-


18,160,281

       Loss on abandonment and write-off of long-lived assets 


-


-


6,603,028

Income from operations 


86,932,518


74,489,160


32,217,468








Other income (expenses)







       Equity in income of an equity method investee 


2,170,473


2,665,881


1,858,171

       Change in fair value of derivative liabilities 


-


1,769,140


11,974,834

       Interest income 


4,433,326


2,910,297


1,356,950

       Interest expense 


(1,134,952)


(1,269,850)


(4,670,606)

       Other income (expense), net 


-


570,511


(453,949)

Total other income, net 


5,468,847


6,645,979


10,065,400








Earnings before income tax expense 


92,401,365


81,135,139


42,282,868








Income tax expense 


15,540,301


15,163,147


10,899,513








Net income 


76,861,064


65,971,992


31,383,355








Less: Net income attributable to noncontrolling interest 


22,259,513


20,749,803


13,201,645










54,601,551


45,222,189



Net income attributable to China Biologic Products, Inc. 




18,181,710








Net income per share of common stock: 







       Basic 


2.05


1.73


0.73

       Diluted 


1.96


1.62


0.37

Weighted average shares used in computation: 







       Basic 


26,410,819


26,153,540


25,028,796

       Diluted 


27,572,111


26,839,723


26,654,662








Net income 


76,861,064


65,971,992


31,383,355








Other comprehensive income:







Foreign currency translation adjustment, net of nil income taxes 


9,126,218


1,735,492


6,846,721








Comprehensive income 


85,987,282


67,707,484


38,230,076








Less: Comprehensive income attributable to noncontrolling interest 


23,951,559


21,163,655


15,320,805








Comprehensive income attributable to China Biologic Products, Inc. 


62,035,723


46,543,829


22,909,271

   

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS








December 31, 


December 31, 



2013


2012



USD


USD

ASSETS 





Current Assets 





   Cash and cash equivalents


144,138,487


129,609,317

   Time deposit


6,608,612


-

   Accounts receivable, net of allowance for doubtful accounts 


17,270,132


11,206,244

   Inventories 


88,634,855


75,679,173

   Prepayments and other current assets


7,641,061


5,664,919

         Total Current Assets 


264,293,147


222,159,653






Property, plant and equipment, net 


73,149,072


51,325,177

Intangible assets, net 


2,585,232


3,541,582

Land use rights, net 


8,213,145


5,818,709

Deposits related to land use rights


13,667,130


14,752,574

Restricted cash and deposit


30,523,674


2,912,145

Equity method investment 


11,349,807


10,537,310

         Total Assets 


403,781,207


311,047,150






LIABILITIES AND STOCKHOLDERS' EQUITY 





Current liabilities 





   Short-term bank loans 


9,822,000


7,935,000

   Accounts payable 


4,445,732


2,908,624

   Due to related parties 


7,206,970


4,081,624

   Other payables and accrued expenses 


34,852,740


25,423,349

   Advance from customers 


2,908,853


2,857,420

   Income tax payable 


4,202,405


4,513,075

         Total Current Liabilities 


63,438,700


47,719,092






Long-term bank loans


30,000,000


-

Deferred income


3,003,895


2,912,145

Other liabilities 


3,369,003


2,996,749

         Total Liabilities 


99,811,598


53,627,986






Stockholders' Equity 





   Common stock:





par value $0.0001;





100,000,000 shares authorized;





27,341,744 and 26,629,615 shares issued at December 31, 2013 and
2012, respectively;





25,862,040 and 26,629,615 shares outstanding at December 31, 2013
and 2012, respectively


2,734


2,663

   Additional paid-in capital 


72,031,864


62,251,731

   Treasury stock: 1,479,704 and nil shares at December 31, 2013 and 2012,
   respectively, at cost


(29,594,080)


-






   Retained earnings


173,744,551


119,143,000

   Accumulated other comprehensive income 


21,506,494


14,072,322

   Total equity attributable to China Biologic Products, Inc. 


237,691,563


195,469,716






   Noncontrolling interest 


66,278,046


61,949,448






         Total Stockholders' Equity 


303,969,609


257,419,164






   Commitments and contingencies 


-


-






         Total Liabilities and Stockholders' Equity 


403,781,207


311,047,150

   

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS



For the Years Ended 


December 31, 


December 31, 


December 31, 


2013


2012


2011


USD


USD


USD

CASH FLOWS FROM OPERATING ACTIVITIES: 






   Net income 

76,861,064


65,971,992


31,383,355

  Adjustments to reconcile net income to net cash provided by operating activities:      






               Depreciation 

6,096,650


5,792,418


4,253,661

               Amortization

1,365,734


3,088,320


3,394,808

               (Gain) loss on sale of property, plant and equipment

(123,777)


828,296


166,934

               Impairment loss of goodwill 

-


-


18,160,281

               Loss on abandonment and write-off of long-lived assets 

-


-


6,603,028

               Provision for (reversal of) allowance for doubtful accounts, net 

31,567


(1,904)


(19,611)

               Provision for (reversal of) doubtful accounts - other receivables and prepayments 

65,094


110,123


(10,254)

               Write-down of obsolete inventories 

-


-


270,929

               Deferred tax expense (benefit) 

112,632


1,127,433


(2,595,103)

               Share-based compensation 

5,050,796


4,544,927


4,896,232

               Change in fair value of derivative liabilities 

-


(1,769,140)


(11,974,834)

               Amortization of deferred note issuance cost 

-


-


91,945

               Amortization of discount on convertible notes 

-


-


3,503,767

               Equity in income of an equity method investee 

(2,170,473)


(2,665,881)


(1,858,171)

Change in operating assets and liabilities: 






               Accounts receivable 

(5,667,386)


5,689,638


(6,126,742)

               Prepayment and other current assets 

(624,159)


(268,498)


(711,740)

               Inventories 

(10,432,492)


(3,750,200)


(17,079,263)

               Accounts payable 

1,621,917


(2,184,674)


431,836

               Other payables and accrued expenses 

2,534,476


(3,210,777)


6,061,066

               Advance from customers 

(38,086)


(2,034,138)


1,140,386

               Due to related parties 

66,349


734,037


-

               Income tax payable 

(446,911)


(904,655)


(1,512,591)

 Net cash provided by operating activities 

74,302,995


71,097,317


38,469,919







 CASH FLOWS FROM INVESTING ACTIVITIES:






   Payment for property, plant and equipment 

(20,492,159)


(13,886,045)


(7,968,870)

   Payment for intangible assets and land use rights 

(1,327,148)


(14,059,397)


(424,971)

   Refund of deposits related to land use right

2,100,150


-


-

   Dividends received 

565,425


1,109,115


1,209,880

   Purchase of time deposit

(6,608,612)


-


-

   Proceeds from sale of property, plant and equipment

194,749


83,134


56,709

Net cash used in investing activities 

(25,567,595)


(26,753,193)


(7,127,252)







CASH FLOWS FROM FINANCING ACTIVITIES: 






   Proceeds from stock option exercised 

5,394,070


727,317


300,000

   Proceeds from warrants exercised 

-


4,500,000


-

   Payment for share repurchase

(29,594,080)


-


-

   Proceeds from short-term bank loans 

9,693,000


11,076,100


18,595,200

   Repayment of short-term bank loans 

(8,014,000)


(14,286,800)


(10,847,200)

   Proceeds from long-term bank loans 

30,000,000


-


-

   Payment for deposit as security for long-term bank loans 

(30,000,000)


-


-

   Acquisition of noncontrolling interest

(1,963,913)


-


(7,635,000)

   Dividends paid by subsidiaries to noncontrolling interest

(16,931,149)


(7,120,693)


(10,489,504)

   Contribution from noncontrolling interest

2,891,422


-


-

 Net cash used in financing activities 

(38,524,650)


(5,104,076)


(10,076,504)







EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH 

4,318,420


957,434


3,204,304







NET INCREASE IN CASH AND CASH EQUIVALENTS

14,529,170


40,197,482


24,470,467







Cash and cash equivalents at beginning of year 

129,609,317


89,411,835


64,941,368







Cash and cash equivalents at end of year 

144,138,487


129,609,317


89,411,835







Supplemental cash flow information 






   Cash paid for income taxes 

15,947,939


14,940,369


15,007,206

   Cash paid for interest expense 

347,602


446,381


890,312

   Noncash investing and financing activities: 






          Convertible notes conversion 

-


-


12,972,000

          Transfer from prepayments and deposits to property, plant and equipment 

7,728,824


38,452


959,660

          Land use right acquired with prepayments made in prior periods 

1,147,561


-


312,060

          Acquisition of property, plant and equipment included in payables 

4,252,428


104,300


83,226

          Exercise of warrants that were liability classified 

-


3,641,279


-

          Restricted cash spent for property, plant and equipment

2,928,421


-


-

   

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 




For the Three Months Ended



December 31, 


December 31, 



2013


2012



USD


USD

Adjusted Net Income Attributable to the Company - Non GAAP


9,623,074


7,279,757

Diluted EPS - Non GAAP


0.35


0.27

Non-cash employee stock compensation


(795,332)


(1,470,795)

Net Income Attributable to the Company


8,827,742


5,808,962

Weighted average number of shares used in computation of Non GAAP diluted EPS


26,910,788


27,147,351








For the Years Ended



December 31, 


December 31, 



2013


2012



USD


USD

Adjusted Net Income Attributable to the Company - Non GAAP


58,974,178


47,997,976

Diluted EPS - Non GAAP


2.12


1.79

Non-cash employee stock compensation


(4,372,627)


(4,544,927)

Gain from change in fair value of warrants


-


1,769,140

Net Income Attributable to the Company


54,601,551


45,222,189

Weighted average number of shares used in computation of Non GAAP diluted EPS


27,572,111


26,839,723

SOURCE China Biologic Products, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArchon, he served as a VP and Principal Analyst with Constellation Group. He is a member of the Boulder (Colo.) Brain Trust, an organization with a mission “to benefit the Business Intelligence and data management industry by providing pro bono exchange of information between vendors and independent analysts on new trends and technologies and to provide vendors with constructive feedback on their of...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...
Innodisk is a service-driven provider of industrial embedded flash and DRAM storage products and technologies, with a focus on the enterprise, industrial, aerospace, and defense industries. Innodisk is dedicated to serving their customers and business partners. Quality is vitally important when it comes to industrial embedded flash and DRAM storage products. That’s why Innodisk manufactures all of their products in their own purpose-built memory production facility. In fact, they designed and built their production center to maximize manufacturing efficiency and guarantee the highest quality of our products.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. Download Slide Deck: ▸ Here
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. Over the summer Gartner released its much anticipated annual Hype Cycle report and the big news is that Internet of Things has now replaced Big Data as the most hyped technology. Indeed, we're hearing more and more about this fascinating new technological paradigm. Every other IT news item seems to be about IoT and its implications on the future of digital business.
BSQUARE is a global leader of embedded software solutions. We enable smart connected systems at the device level and beyond that millions use every day and provide actionable data solutions for the growing Internet of Things (IoT) market. We empower our world-class customers with our products, services and solutions to achieve innovation and success. For more information, visit www.bsquare.com.